Schering Corporation

Imtiaz A Chaudry

Joel A Sequeira

Elliot I Stupak

Francis M Cuss

James E Patrick

Nagamani Nagabhushan

Mitchell Cayen

Keith B Nolop

Winston A Vadino

Stephen M Liebowitz

Frank E Bowen

Farah J Munayyer

Frank Guazzo

Zachary Yim

Julianne Fassberg

Michael Kopcha

Wing-Kee Philip Cho

Michael A Zupon

Edward M Rudnic

Patricia W Kogan

David Hamilton Harris

Eric M Bonnem

Julianne Berry

Varda Ecker

Yogendra M Shah

Martin Zupon

The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.

Use of mometasone furoate for treating upper airway diseases

Use of mometasone furoate for treating airway passage and lung diseases

An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid such as a salt of ethylenediaminetetraacetic acid.

Stabilized antihistamine syrup

Aerosol formulations substantially free of chlorofluorocarbons, for oral and/or nasal administration, are described. The formulations comprise 1,1,1,2-tetrafluoroethane, a medicament, optionally an excipient and optionally a surfactant. Methods of treatment using the formulations also are described.

Non-chlorofluorocarbon aerosol formulations

Aerosol formulations substantially free of chlorofluorocarbons, for oral and/or nasal administration are described. The formulations comprise 1,1,1,2 tetrafluoroethane, a medicament, optionally an excipient and optionally a surfactant. Methods of treatment utilizing the formulations also are described.

Aerosol formulations of albuterol and 1,1,1,2-tetrafluoroethane

An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin and a process for making such solid dosage forms are disclosed.

Orally administrable solid ribavirin dosage forms and process for making them

An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin is disclosed.

Orally administrable solid dosage form

An aqueous nebulizer suspension contains water, mometasone furoate monohydrate, a nonionic surfactant, a soluble salt and optionally a pH buffer. The suspension may be prepared by ultrasonication or jet milling techniques.

Mometasone furoate suspensions for nebulization

The invention relates to suspension aerosol formulations which exhibit stable particle sizes, containing mometasone furoate, about 1 to about 10 weight percent ethanol and 1,1,1,2,3,3,3-Heptafluoropropane as the propellant. A surfactant, such as oleic acid, can also be included. These formulations are suitable for use in metered dose inhalers.

Chlorofluorocarbon-free mometasone furoate aerosol formulations

Growing community of inventors

North Caldwell, NJ, United States of America

Imtiaz A Chaudry